[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361736-105":59,"doc-detail-361736-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","expression-profiles-of-five-common-cancer-membrane-protein-antigens-collected-for-the-development-of-cocktail-car-t-cell-therapies-applicable-to-most-solid-cancer-patients","Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients","","Although CD19 CAR-T has shown strong results for B-cell blood cancers, solid tumors remain challenging due to the limited availability of membrane protein antigens specifically expressed on cancer cell surfaces. The study targets cancer-antigen heterogeneity by using multiple antigens simultaneously. Immunohistochemical analyses examined ROBO1, EphB4, CLDN1, LAT1, and previously studied GPC3 across solid cancer specimens. EphB4, CLDN1, and LAT1 were frequently membrane-restricted on cancer cells, supporting their value as CAR-T targets for diverse solid cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/expression-profiles-of-five-common-cancer-membrane-protein-antigens-collected-for-the-development-of-cocktail-car-t-cell-therapies-applicable-to-most-solid-cancer-patients/361736/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/expression-profiles-of-five-common-cancer-membrane-protein-antigens-collected-for-the-development-of-cocktail-car-t-cell-therapies-applicable-to-most-solid-cancer-patients/361736.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is developing CAR-T therapy for solid cancers harder than for blood cancers?","Question",{"text":112,"@type":113},"Because successful CAR-T approaches require suitable antigens on cancer-cell membrane surfaces, and solid tumors often have few membrane protein antigens that are specifically expressed on those surfaces.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the main strategy used to address cancer antigen heterogeneity?",{"text":117,"@type":113},"Target multiple cancer antigens simultaneously by developing a cocktail CAR-T approach, rather than relying on a single antigen.",{"name":119,"@type":110,"acceptedAnswer":120},"Which antigens showed membrane-restricted expression on solid cancer cells in this study?",{"text":121,"@type":113},"EphB4, CLDN1, and LAT1 were frequently expressed only on the cell membrane of cancer cells across various solid cancers, suggesting they are suitable CAR-T targets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361736,1790197410,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Article  \nExpression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients  \nTetsuya Nakatsura *, Kazumasa Takenouchi, Jun Kataoka, Yusuke Ito, Sae Kikuchi, Hiroki Kinoshita, Kazunobu Ohnuki, Toshihiro Suzuki and Nobuo Tsukamoto  \nAcademic Editor: AbdelkrimHmadcha  \nReceived: 23 January 2025  \nRevised: 21 February 2025  \nAccepted: 25 February 2025  \nPublished: 27 February 2025  \nCitation: Nakatsura, T.; Takenouchi, K.; Kataoka, J.; Ito, Y.; Kikuchi, S.; Kinoshita, H.; Ohnuki, K.; Suzuki, T.; Tsukamoto, N. Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients. Int. J. Mol. Sci. 2025, 26, 2145. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26052145  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer  \nCenter, Kashiwa 277-8577, Japan; [katakeno@east.ncc.go.jp](katakeno@east.ncc.go.jp) (K.T.); [jkataoka@east.ncc.go.jp](jkataoka@east.ncc.go.jp) (J.K.);  \n[yusito@east.ncc.go.jp](yusito@east.ncc.go.jp) (Y.I.); [sakikuc4@east.ncc.go.jp](sakikuc4@east.ncc.go.jp) (S.K.); [hirokino@east.ncc.go.jp](hirokino@east.ncc.go.jp) (H.K.);  \n[konuki@east.ncc.go.jp](konuki@east.ncc.go.jp) (K.O.); [toshsuzu@east.ncc.go.jp](toshsuzu@east.ncc.go.jp) (T.S.); [nobutsuk@east.ncc.go.jp](nobutsuk@east.ncc.go.jp) (N.T.)  \n* Correspondence: [tnakatsu@east.ncc.go.jp](tnakatsu@east.ncc.go.jp); Tel.: +81-4-7131-5490  \nAbstract: Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to “overcome the heterogeneity of cancer antigens”. For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. Although ROBO1 and GPC3 are often expressed in cytoplasm, there are also cases in which they are expressed on the cell membrane depending on the type of cancer. On the other hand, it has been revealed that three antigens—EphB4, CLDN1, and LAT1—are frequently expressed only on the cell membrane of cancer cells in various solid cancers, suggesting that they may be ideal targets for CAR-T cell therapy.  \nKeywords: common cancer antigens; CAR-T cell therapy; membrane protein; solid cancer; glypican-3; ROBO1; EphB4; CLDN1; LAT1; cocktail CAR-T  \n1. Introduction  \nWe discovered the cancer-specific antigen glypican-3 (GPC3) and identified peptides that can induce cytotoxic T lymphocytes (CTLs) in an HLA-A24-or-A2-restricted manner and conducted clinical trials of peptide vaccines for hepatocellular carcinoma, ovarian clear cell carcinoma, and pediatric cancer [1–5] . We have experienced successful cases even in advanced cancers, demonstrating the possibility of preventing recurrence. Seven children with childhood cancer who received this vaccine have still been growing healthily and without recurrence for about 10 years. We are currently identifying","cbCaiojEbzDKqKrj","https://ap.wps.com/l/cbCaiojEbzDKqKrj","pdf",8564188,13,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why is developing CAR-T therapy for solid cancers harder than for blood cancers?\",\"answer\":\"Because successful CAR-T approaches require suitable antigens on cancer-cell membrane surfaces, and solid tumors often have few membrane protein antigens that are specifically expressed on those surfaces.\"},{\"question\":\"What was the main strategy used to address cancer antigen heterogeneity?\",\"answer\":\"Target multiple cancer antigens simultaneously by developing a cocktail CAR-T approach, rather than relying on a single antigen.\"},{\"question\":\"Which antigens showed membrane-restricted expression on solid cancer cells in this study?\",\"answer\":\"EphB4, CLDN1, and LAT1 were frequently expressed only on the cell membrane of cancer cells across various solid cancers, suggesting they are suitable CAR-T targets.\"}]","Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients | PDF",1790145434,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65878592c02aa8132e6a87fd27540f05.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f48c43c2671f7aeb69e865079bdd2077.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be80d695cc2b6021bfd48b48f1193e30.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8278db543955532ed1d7db4d1cb5d476.webp",980,1385]